Literature DB >> 26962927

Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

Evan J Lipson1, Serena M Bagnasco1, Jack Moore2, Sekwon Jang3, Manisha J Patel4, Andrea A Zachary4, Drew M Pardoll4, Janis M Taube4, Charles G Drake4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26962927      PMCID: PMC4850555          DOI: 10.1056/NEJMc1509268

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Distant metastases from cutaneous squamous cell carcinoma--analysis of AJCC stage IV.

Authors:  Markus Brunner; Michael J Veness; Sydney Ch'ng; Michael Elliott; Jonathan R Clark
Journal:  Head Neck       Date:  2012-01-20       Impact factor: 3.147

Review 2.  Identification and management of toxicities from immune checkpoint-blocking drugs.

Authors:  Benjamin A Teply; Evan J Lipson
Journal:  Oncology (Williston Park)       Date:  2014-11       Impact factor: 2.990

Review 3.  Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Authors:  Evan J Lipson; Patrick M Forde; Hans-Joerg Hammers; Leisha A Emens; Janis M Taube; Suzanne L Topalian
Journal:  Semin Oncol       Date:  2015-06-10       Impact factor: 4.929

4.  Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.

Authors:  Evan J Lipson; Mabel A Bodell; Edward S Kraus; William H Sharfman
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

  4 in total
  78 in total

Review 1.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

Review 2.  Renal complications of immune checkpoint blockade.

Authors:  Naoka Murakami; Shveta Motwani; Leonardo V Riella
Journal:  Curr Probl Cancer       Date:  2016-12-19       Impact factor: 3.187

Review 3.  Current status of alloimmunity.

Authors:  Thiago J Borges; Naoka Murakami; Leonardo V Riella
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

4.  Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma.

Authors:  Andreas Varkaris; David W Lewis; Francis W Nugent
Journal:  Am J Gastroenterol       Date:  2017-12       Impact factor: 10.864

5.  Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

Authors:  Luis E Aguirre; Maria E Guzman; Gilberto Lopes; Judith Hurley
Journal:  Oncologist       Date:  2018-11-09

Review 6.  Cutaneous squamous cell carcinoma in the organ transplant recipient.

Authors:  Kristin Bibee; Andrew Swartz; Shaum Sridharan; Cornelius H L Kurten; Charles B Wessel; Heath Skinner; Dan P Zandberg
Journal:  Oral Oncol       Date:  2020-02-14       Impact factor: 5.337

Review 7.  Programmed T cell differentiation: Implications for transplantation.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Cell Immunol       Date:  2020-03-29       Impact factor: 4.868

Review 8.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

Review 9.  Molecular assessment of disease states in kidney transplant biopsy samples.

Authors:  Philip F Halloran; Konrad S Famulski; Jeff Reeve
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

10.  Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.

Authors:  Kang Miao; Li Zhang
Journal:  Interdiscip Sci       Date:  2021-06-21       Impact factor: 2.233

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.